This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quidel's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Our placement rate improved during the quarter which is encouraging given the low prevalence rate and customer interest in discussing flu this time of the year. Other assays for hCG strep and RSV are planned to follow shortly and we would expect by the first quarter of 2013 to have a menu of four tests in the United States and six tests in Europe with still others to follow throughout the year.

The other key near-term initiative is AmpliVue our handheld disposable molecular platform that combines isothermal amplification with traditional lateral flow detection. We received CE mark for our C. difficile product in March, completed U.S. clinical trials in the second quarter and have been building inventor for our European product launch in the fall. And then anticipated launch here in the U.S. before the end of the year. We expect assays for MRSA for blood culture confirmation, (inaudible) strep and is to follow shortly.

I’d like now to turn to the medium to longer term timeframe in terms of likely commercial impact. During the quarter we progress with the rest of our molecular program. We received CE mark for our direct specimen PCR assay for C. difficile in early and are conducting U.S. clinical trials now.

We completed U.S. clinical trials for our RSV and human Metapneumovirus assays. Our HSV and VZV assays remain a development in our on track inter clinical trial this half of 2012 with other PCR assays to follow shortly.

As I previously disclosed we are aiming to have a menu of 20 targets that can be run on our Wildcat platform when it launches in 2014, and at that this stage I remain confident that we can see that hurdle.

I should mention that we recently entered into a partnership with Life Technologies for the development and commercialization of real-time PCR assays on their new instrument system. Many of these assays will be portable to Wildcat as well. With respect to project Wildcat, specifically with development of the platform, we remain on track at this stage. Primary focus is ensuring that we keep our commitment to the Northwestern Global Health Foundation. That commitment is to develop and deliver an inexpensive fully integrated molecular platform that can reduce the cost of HIV viral load and TB testing in Africa in 2014. We believe that the key to achieving this goal is development of a low cost cartridge and that our proprietary (inaudible) extraction technology is the key to delivering on that promise.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs